TET2 and neoplasm: Fortunately, TET2 KO significantly sensitizes a variety of tumor cells to mTORC1 inhibition by rapamycin (Fig. 6f, g), temsirolimus (Supplementary Fig. S6k, l) or everolimus (Supplementary Fig. S6m, n), which is recaptured in mouse model.